Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.

William Joseph Chapin,Wei-Ting Hwang,Thomas B. Karasic,Anne Marie McCarthy,David E. Kaplan

Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.

2021

William Joseph Chapin
Wei-Ting Hwang
Thomas B. Karasic
Anne Marie McCarthy
David E. Kaplan

4102Background: Up to 90% of cases of hepatocellular carcinoma (HCC) in the U.S. occur in patients with cirrhosis. As prognosis in patients with decompensated cirrhosis may be more related to liver...

Keywords:

Gastroenterology
Internal medicine
Systemic therapy
Lenvatinib
first line
Nivolumab
Medicine
Hepatocellular carcinoma
Cirrhosis
Child-Pugh Class B
Sorafenib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations